# Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics Holdings, Inc. is a company headquartered in Princeton, NJ, United States.

## Company overview

- **Legal name:** Sonnet BioTherapeutics Holdings, Inc.
- **Former names in filing history:** Chanticleer Holdings, Inc. (2005-05-10 to 2020-03-31); TULVINE SYSTEMS INC (2000-03-07 to 2005-03-31)
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Princeton, NJ, United States
- **Incorporated in:** DE
- **Fiscal year end:** September 30
- **SEC CIK:** 0001106838

## About

Sonnet BioTherapeutics Holdings, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001106838, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2025-12-16, it reported annual revenue of USD 1,000,000; net income of USD -16,011,487; total assets of USD 14,884,558 for the fiscal period ended 2025-09-30. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2025 (period ended 2025-09-30)

- **Revenue:** $1.0M (USD 1,000,000)
- **Net income:** -$16.0M (USD -16,011,487)
- **Total assets:** $14.9M (USD 14,884,558)
- **Cash and equivalents:** $5.1M (USD 5,120,264)
- **Operating cash flow:** -$12.8M (USD -12,827,199)

### FY2024 (period ended 2024-09-30)

- **Revenue:** $18,626 (USD 18,626)
- **Net income:** -$7.4M (USD -7,437,232)
- **Total assets:** $2.8M (USD 2,771,030)
- **Cash and equivalents:** $149,456 (USD 149,456)
- **Operating cash flow:** -$8.6M (USD -8,607,723)

### FY2023 (period ended 2023-09-30)

- **Revenue:** $147,805 (USD 147,805)
- **Net income:** -$18.8M (USD -18,832,694)
- **Total assets:** $5.4M (USD 5,429,478)
- **Operating cash flow:** -$21.3M (USD -21,341,842)

### FY2022 (period ended 2022-09-30)

- **Revenue:** $349,943 (USD 349,943)
- **Net income:** -$29.7M (USD -29,721,841)
- **Total assets:** $5.8M (USD 5,830,012)
- **Operating cash flow:** -$27.7M (USD -27,687,278)
- **Later filings:** Operating cash flow: shown as originally filed; later filings report different values for the same periods.

## Recent SEC filings

- Form 10-K/A — filed 2026-07-17 — period 2025-09-30 — 10-K/A
- Form 10-K — filed 2025-12-16 — period 2025-09-30 — 10-K
- Form 8-K — filed 2025-12-03 — period 2025-12-02 — 8-K
- Form 8-K — filed 2025-12-02 — period 2025-12-02 — 8-K
- Form 8-K — filed 2025-11-18 — period 2025-11-18 — 8-K
- Form 8-K — filed 2025-09-29 — period 2025-09-26 — 8-K
- Form DEF 14A — filed 2025-08-26 — period 2025-08-26 — DEF 14A
- Form 10-Q — filed 2025-08-13 — period 2025-06-30 — 10-Q
- Form 8-K — filed 2025-08-01 — period 2025-07-31 — 8-K
- Form 8-K — filed 2025-07-25 — period 2025-07-23 — 8-K
- Form 8-K — filed 2025-07-18 — period 2025-07-18 — 8-K
- Form 8-K — filed 2025-07-14 — period 2025-07-11 — 8-K

---

Updated: 2026-10-23T20:13:49Z

Canonical page: https://altss.com/profile/sonnet-biotherapeutics-holdings-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology